MNKD-201 in IPF will Have a Ph1b Study in the U.S. Management also disclosed the plan to initiate a Ph1b trial in approximately 30 IPF patients, who will receive seven days of treatment with MNKD-201 at the Ph2 doses. Data to be available in 2Q26 will confirm DPI's tolerability in IPF patients and
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.